A randomised, single-blind, placebo-controlled trial to investigate safety, tolerability, and pharmacokinetics of single rising doses of BI 3000202 administered as tablet to healthy male subjects, and a randomised, open-label, single-dose, two-way cross-over relative bioavailability comparison of BI 3000202 as tablet with and without food in healthy male subjects

SRD part: Occurrence of any treatment-emergent adverse event assessed as drug-related by the investigator. This is expressed as the percentage of subjects treated with investigational drug who experience such an event., FE part: AUC0-24 (area under the concentration-time curve of the analyte in plasma over the dosing interval 0 to 24 hours), FE part: Cmax (maximum measured concentration of the analyte in plasma)